Sasaki Mark M, Skol Andrew D, Hungate Eric A, Bao Riyue, Huang Lei, Kahn Stacy A, Allan James M, Brant Steven R, McGovern Dermot P B, Peter Inga, Silverberg Mark S, Cho Judy H, Kirschner Barbara S, Onel Kenan
*Department of Pediatrics and †Center for Research Informatics, The University of Chicago, Chicago, Illinois; ‡Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom; §Meyerhoff Inflammatory Bowel Disease Center, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; ‖Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland; ¶F. Widjaja Family Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California; **Department of Genetics and Genomic Sciences and ††Zane Cohen Centre for Digestive Diseases, Department of Medicine, Mount Sinai Hospital, The University of Toronto, Toronto, Ontario, Canada; and ‡‡Department of Medicine, The Icahn School of Medicine at Mount Sinai, New York, New York.
Inflamm Bowel Dis. 2016 Jan;22(1):20-7. doi: 10.1097/MIB.0000000000000610.
Rare variants (<1%) likely contribute significantly to risk for common diseases such as inflammatory bowel disease (IBD) in specific patient subsets, such as those with high familiality. They are, however, extraordinarily challenging to identify.
To discover candidate rare variants associated with IBD, we performed whole-exome sequencing on 6 members of a pediatric-onset IBD family with multiple affected individuals. To determine whether the variants discovered in this family are also associated with nonfamilial IBD, we investigated their influence on disease in 2 large case-control (CC) series.
We identified 2 rare variants, rs142430606 and rs200958270, both in the established IBD-susceptibility gene IL17REL, carried by all 4 affected family members and their obligate carrier parents. We then demonstrated that both variants are associated with sporadic ulcerative colitis (UC) in 2 independent data sets. For UC in CC 1: rs142430606 (odds ratio [OR] = 2.99, Padj = 0.028; minor allele frequency [MAF]cases = 0.0063, MAFcontrols = 0.0021); rs200958270 (OR = 2.61, Padj = 0.082; MAFcases = 0.0045, MAFcontrols = 0.0017). For UC in CC 2: rs142430606 (OR = 1.94, P = 0.0056; MAFcases = 0.0071, MAFcontrols = 0.0045); rs200958270 (OR = 2.08, P = 0.0028; MAFcases = 0.0071, MAFcontrols = 0.0042).
We discover in a family and replicate in 2 CC data sets 2 rare susceptibility variants for IBD, both in IL17REL. Our results illustrate that whole-exome sequencing performed on disease-enriched families to guide association testing can be an efficient strategy for the discovery of rare disease-associated variants. We speculate that rare variants identified in families and confirmed in the general population may be important modifiers of disease risk for patients with a family history, and that genetic testing of these variants may be warranted in this patient subset.
罕见变异(<1%)可能在特定患者亚组(如家族聚集性高的患者)中对常见疾病(如炎症性肠病(IBD))的风险有显著贡献。然而,识别这些变异极具挑战性。
为发现与IBD相关的候选罕见变异,我们对一个有多例受累个体的儿童期发病IBD家族的6名成员进行了全外显子组测序。为确定在该家族中发现的变异是否也与非家族性IBD相关,我们在2个大型病例对照(CC)系列中研究了它们对疾病的影响。
我们在已确定的IBD易感基因IL17REL中鉴定出2个罕见变异,rs142430606和rs200958270,所有4名受累家庭成员及其必然携带变异的父母均携带这两个变异。然后我们证明这两个变异在2个独立数据集中均与散发性溃疡性结肠炎(UC)相关。对于CC 1中的UC:rs142430606(优势比[OR]=2.99,校正P值=0.028;病例组次要等位基因频率[MAF]病例=0.0063,对照组MAF=0.0021);rs200958270(OR=2.61,校正P值=0.082;MAF病例=0.0045,对照组MAF=0.0017)。对于CC 2中的UC:rs142430606(OR=1.94,P=0.0056;MAF病例=0.0071,对照组MAF=0.0045);rs200958270(OR=2.08,P=0.0028;MAF病例=0.0071,对照组MAF=0.0042)。
我们在一个家族中发现并在2个CC数据集中验证了IBD的2个罕见易感变异,均位于IL17REL基因中。我们的结果表明,对疾病富集家族进行全外显子组测序以指导关联测试可能是发现罕见疾病相关变异的有效策略。我们推测在家族中鉴定出并在普通人群中得到确认的罕见变异可能是有家族病史患者疾病风险的重要修饰因子,并且对这些变异进行基因检测可能适用于该患者亚组。